Synthetic Biologics' C. difficile mid-stage study meets main goal

Reuters Health Information: Synthetic Biologics' C. difficile mid-stage study meets main goal

Synthetic Biologics' C. difficile mid-stage study meets main goal

Last Updated: 2017-01-05

By Reuters Staff

(Reuters) - Synthetic Biologics Inc said its experimental treatment designed to reduce antibiotic-resistant infections - notably life-threatening C. difficile - outperformed a placebo in a clinical trial.

The company's oral enzyme, ribaxamase, met the main goal of significantly reducing Clostridium difficile infection, the most common cause of hospital-associated infectious diarrhea.

Ribaxamase is designed to protect the gut microbiome from disruption caused by certain intravenous (IV) beta-lactam antibiotics. It was tested against a placebo in a 412-patient mid-stage study.

Seven cases of C. difficile infection were reported in the placebo group, compared to two in the ribaxamase group, a preliminary analysis showed.

"Patients receiving ribaxamase achieved a 71.4% relative risk reduction (p-value=0.045) in CDI rates compared to patients receiving placebo. Adverse events reported during this trial were comparable between treatment and placebo arms," the company said in a news release.

Antibiotic-resistant infections are a grave threat to public health. A Reuters investigation has found that infection-related deaths are going uncounted, hindering the ability of the United States to fight the scourge.

© Copyright 2013-2019 GI Health Foundation. All rights reserved.
This site is maintained as an educational resource for US healthcare providers only. Use of this website is governed by the GIHF terms of use and privacy statement.